What Semaglutide S20 actually is

The 20mg vial is our maintenance concentration for patients stabilized at higher semaglutide doses. The pharmacology is identical to brand-name Wegovy at the 2.4mg/week target dose; the 20mg vial delivers convenient steady-state dosing for long-term use.

Once weight loss stabilizes and tolerability is established, this concentration supports the cardiovascular and metabolic maintenance phase. The SELECT trial demonstrated reduced major adverse cardiovascular events in maintenance-dose patients with obesity.¹

At Luxbae, Semaglutide S20 is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.

Mechanism — Maintenance steady-state

Sustained GLP-1 agonism at steady-state dose provides ongoing appetite, glycemic, and cardiovascular benefit.²

What the research shows

Maintenance weight loss. Sustained body-weight reduction across STEP-trial follow-up data.

Cardiovascular protection. SELECT-trial MACE reduction in obesity cohort.¹

Glycemic stability. Long-term A1C improvement.

Side effects: Generally well-tolerated at maintenance. Occasional GI symptoms during dose adjustments.

FDA note: Brand-name semaglutide (Wegovy) is FDA-approved at 2.4mg weekly; compounded under shortage rules.

Semaglutide S20 FAQ

Will I take this forever?
Often long-term given weight-regain risk on discontinuation. Discussed individually.

Cardiovascular benefit at this dose?
Yes — SELECT trial evidence applies.

References

1. Lincoff AM, et al. Semaglutide SELECT. N Engl J Med. 2023;389(24):2221-2232.
2. Wilding JPH, et al. STEP-1. N Engl J Med. 2021;384(11):989-1002.
3. Drucker DJ. Mechanisms of GLP-1. Cell Metab. 2018;27(4):740-756.